| 2025-01-08 | +32.2% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-07-16 | +25.6% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-07-16 | +25.6% | legal | SEC EDGAR | ANGO 8-K: 2.02 and (SEC Filing) |
| 2022-10-06 | -22.4% | legal | SEC EDGAR | ANGO 8-K: 8.01 (SEC Filing) |
| 2022-10-06 | -22.4% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-10-03 | -21.0% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-01-05 | -19.2% | legal | SEC EDGAR | ANGO 8-K: 2.02, 5.02, 7.01 (SEC Filing) |
| 2023-03-30 | -19.1% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-02 | -18.2% | earnings | GuruFocus.com | AngioDynamics Inc (ANGO) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Financial ... |
| 2026-04-02 | -18.2% | earnings | Moby | AngioDynamics, Inc. Q3 2026 Earnings Call Summary |
| 2026-04-02 | -18.2% | earnings | MarketBeat | AngioDynamics Q3 Earnings Call Highlights |
| 2026-04-02 | -18.2% | earnings | Zacks | AngioDynamics (ANGO) Reports Q3 Loss, Tops Revenue Estimates |
| 2026-04-02 | -18.2% | earnings | Associated Press | AngioDynamics: Fiscal Q3 Earnings Snapshot |
| 2026-04-02 | -18.2% | earnings | Seeking Alpha | AngioDynamics signals FY2026 adjusted EBITDA of $10M-$12M while raising net sales guidance to $313.5M-$315.5M |
| 2026-04-02 | -18.2% | earnings | Seeking Alpha | AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript |
| 2026-04-02 | -18.2% | earnings | Seeking Alpha | AngioDynamics, Inc. 2026 Q3 - Results - Earnings Call Presentation |
| 2026-04-02 | -18.2% | earnings | Seeking Alpha | AngioDynamics Non-GAAP EPS of -$0.07 beats by $0.04, revenue of $78.42M beats by $1.65M |
| 2026-04-02 | -18.2% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-02 | -18.2% | earnings | Quiver Quantitative | ANGIODYNAMICS ($ANGO) Releases Q3 2026 Earnings | ANGO Stock News - Quiver Quantitative |
| 2026-04-02 | -18.2% | earnings | Yahoo Finance | AngioDynamics (ANGO) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance |
| 2026-04-02 | -18.2% | earnings | Stock Titan | AngioDynamics (NASDAQ: ANGO) Q3 2026 revenue up 9% while net loss grows - Stock Titan |
| 2026-04-02 | -18.2% | earnings | Seeking Alpha | AngioDynamics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2026-04-02 - Seeking Alpha |
| 2026-04-02 | -18.2% | news | Stock Titan | [8-K] ANGIODYNAMICS INC Reports Material Event - Stock Titan |
| 2026-01-06 | -17.7% | earnings | Seeking Alpha | AngioDynamics raises 2026 revenue guidance to $314M while advancing Med Tech growth |
| 2026-01-06 | -17.7% | earnings | Seeking Alpha | AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript |
| 2026-01-06 | -17.7% | earnings | Seeking Alpha | AngioDynamics, Inc. 2026 Q2 - Results - Earnings Call Presentation |
| 2026-01-06 | -17.7% | earnings | Seeking Alpha | AngioDynamics Non-GAAP EPS of $0.00 beats by $0.10, revenue of $79.43M beats by $3M |
| 2026-01-06 | -17.7% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-06 | -17.7% | news | Benzinga | AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday - Benzinga |
| 2026-01-06 | -17.7% | earnings | marketscreener.com | AngioDynamics, Inc. Revises Earnings Guidance for the Fiscal Year 2026 - marketscreener.com |
| 2024-04-04 | +15.8% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-01-06 | -15.0% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-09-30 | +12.6% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-07 | -11.8% | earnings | TradingView | ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves - TradingView |
| 2026-01-05 | -11.0% | earnings | Seeking Alpha | AngioDynamics FQ2 2026 Earnings Preview |
| 2025-07-15 | -10.6% | news | Seeking Alpha | AngioDynamics projects $305M–$310M FY26 sales as Med Tech drives double-digit growth |
| 2025-07-15 | -10.6% | earnings | Seeking Alpha | AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript |
| 2025-07-15 | -10.6% | earnings | Seeking Alpha | AngioDynamics, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2025-07-15 | -10.6% | earnings | Seeking Alpha | AngioDynamics Non-GAAP EPS of -$0.03 beats by $0.09, revenue of $80.16M beats by $5.9M |
| 2025-07-15 | -10.6% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-08 | -10.4% | earnings | Yahoo Finance | Is AngioDynamics' (ANGO) Higher Sales Guidance Enough To Offset CEO Transition Concerns? - Yahoo Finance |
| 2023-01-05 | +10.3% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-04-07 | +9.6% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-06-08 | +7.2% | legal | SEC EDGAR | ANGO 8-K: 8.01 and (SEC Filing) |
| 2022-11-23 | -7.1% | legal | SEC EDGAR | ANGO 8-K: 8.01 (SEC Filing) |
| 2021-07-13 | -6.8% | legal | SEC EDGAR | ANGO 8-K: 2.02 and 7.01 (SEC Filing) |
| 2023-10-04 | -6.6% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-06 | -6.4% | earnings | Zacks | ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down |
| 2026-04-06 | -6.4% | analyst | Investing.com | Freedom Broker initiates AngioDynamics stock coverage with buy rating - Investing.com |
| 2026-04-06 | -6.4% | earnings | Yahoo Finance | ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down - Yahoo Finance |
| 2024-04-01 | +6.3% | legal | SEC EDGAR | ANGO 8-K: 1.01 (SEC Filing) |
| 2026-03-31 | +6.2% | news | Stock Titan | AngioDynamics investors can watch Needham conference webcast April 14 - Stock Titan |
| 2025-04-02 | +6.0% | news | Seeking Alpha | Biggest stock movers Wednesday: NCNO, TTEC, EWTX, BB, ANGO and more |
| 2025-04-02 | +6.0% | news | Seeking Alpha | AngioDynamics targets 14%-16% MedTech growth for fiscal 2025 driven by thrombectomy and NanoKnife adoption |
| 2025-04-02 | +6.0% | earnings | Seeking Alpha | AngioDynamics, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-04-02 | +6.0% | earnings | Seeking Alpha | AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript |
| 2025-04-02 | +6.0% | earnings | Seeking Alpha | AngioDynamics beats top-line and bottom-line estimates; updates FY25 outlook |
| 2025-04-02 | +6.0% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-07-12 | +5.8% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-21 | +5.3% | news | Finviz | Reasons to Hold AngioDynamics Stock in Your Portfolio for Now - Finviz |
| 2025-10-02 | +5.0% | news | Seeking Alpha | AngioDynamics: Discounted Sales Multiple With Real Growth Engines |
| 2025-10-02 | +5.0% | news | Seeking Alpha | AngioDynamics raises sales outlook to $313M for FY26 as Med Tech segment accelerates |
| 2025-10-02 | +5.0% | earnings | Seeking Alpha | AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript |
| 2025-10-02 | +5.0% | earnings | Seeking Alpha | AngioDynamics, Inc. 2026 Q1 - Results - Earnings Call Presentation |
| 2025-10-02 | +5.0% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-10-02 | +5.0% | earnings | Yahoo Finance | AngioDynamics Inc (ANGO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ... - Yahoo Finance |
| 2025-10-02 | +5.0% | news | Seeking Alpha | AngioDynamics: Discounted Sales Multiple With Real Growth Engines (NASDAQ:ANGO) - Seeking Alpha |
| 2025-10-02 | +5.0% | news | Benzinga | Stock Market Today: Dow Futures Slip, S&P 500 Rises Amid Mixed Trade—Berkshire, Occidental, Fermi In Focu - Benzinga |
| 2026-04-05 | -5.0% | news | Seeking Alpha | AngioDynamics Growing, But With More Noise Than The Street Likes |
| 2026-04-05 | -5.0% | news | Seeking Alpha | AngioDynamics Growing, But With More Noise Than The Street Likes (NASDAQ:ANGO) - Seeking Alpha |
| 2025-07-21 | +4.9% | legal | Stock Titan | ANGO SEC Filings - Angiodynamics 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2022-11-04 | +4.8% | legal | SEC EDGAR | ANGO 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-01-30 | +4.2% | news | Yahoo Finance | Here's Why AngioDynamics (ANGO) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance |
| 2026-04-09 | -4.1% | earnings | MarketBeat | AngioDynamics (NASDAQ:ANGO) Issues FY 2026 Earnings Guidance - MarketBeat |
| 2026-02-09 | +4.1% | news | Stock Titan | Kevin Kotler discloses 5.9% AngioDynamics (ANGO) stake in 13G filing - Stock Titan |
| 2023-07-12 | -4.1% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-04 | +3.7% | earnings | Quiver Quantitative | ANGIODYNAMICS Q2 2026 Earnings Preview: Recent $ANGO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative |
| 2023-08-15 | +3.7% | legal | Seeking Alpha | AngioDynamics gets FDA breakthrough status for AngioVac indication (ANGO) - Seeking Alpha |
| 2024-03-09 | -3.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-01-23 | -3.4% | news | DirectorsTalk Interviews | AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring An 81.88% Potential Upside - DirectorsTalk Interviews |
| 2025-05-28 | +3.2% | legal | SEC EDGAR | ANGO 8-K: 1.01, 2.03 (SEC Filing) |
| 2025-11-10 | +3.1% | news | Seeking Alpha | AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript |
| 2025-12-22 | -2.7% | news | Stock Titan | New York medtech firm to present at J.P. Morgan healthcare conference - Stock Titan |
| 2025-12-05 | -2.5% | legal | DirectorsTalk Interviews | AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 41.95% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews |
| 2025-12-05 | -2.5% | earnings | simplywall.st | The Market Doesn't Like What It Sees From AngioDynamics, Inc.'s (NASDAQ:ANGO) Revenues Yet - simplywall.st |
| 2022-10-17 | -2.5% | analyst | eToro | AngioDynamics Inc (ANGO) Stock Price, News & Analyst Forecast - eToro |
| 2025-10-22 | +2.5% | M&A | GuruFocus | Insider Buying: Lawrence Weiss Acquires Shares of AngioDynamics Inc (ANGO) - GuruFocus |
| 2025-10-22 | +2.5% | news | Quiver Quantitative | Insider Stock Purchases: October 22, 2025 - Quiver Quantitative |
| 2023-06-02 | +2.5% | legal | SEC EDGAR | ANGO 8-K: 8.01 (SEC Filing) |
| 2024-04-05 | +2.2% | analyst | Seeking Alpha | AngioDynamics stock upgraded at Oppenheimer (NASDAQ:ANGO) - Seeking Alpha |
| 2026-01-12 | +2.2% | news | Yahoo Finance | Down 25.0% in 4 Weeks, Here's Why You Should You Buy the Dip in AngioDynamics (ANGO) - Yahoo Finance |
| 2026-03-19 | +2.0% | earnings | Stock Titan | AngioDynamics schedules April 2 earnings call before market open - Stock Titan |
| 2026-02-03 | +2.0% | legal | SEC EDGAR | ANGO 8-K: 5.02 and (SEC Filing) |
| 2023-11-16 | -2.0% | legal | SEC EDGAR | ANGO 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-01-15 | +2.0% | news | Seeking Alpha | AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-15 | +2.0% | news | Seeking Alpha | AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2024-01-22 | +1.9% | legal | SEC EDGAR | ANGO 8-K: 5.02 (SEC Filing) |
| 2025-12-26 | -1.8% | legal | DirectorsTalk Interviews | AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 46.91% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews |
| 2023-06-14 | -1.8% | legal | SEC EDGAR | ANGO 8-K: 1.01, 1.02, 2.01 (SEC Filing) |
| 2026-03-30 | +1.7% | earnings | MarketBeat | Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 18.0% - MarketBeat |
| 2024-02-13 | -1.6% | legal | SEC EDGAR | ANGO 8-K: 5.02 (SEC Filing) |
| 2025-10-26 | -1.6% | earnings | Yahoo Finance | H.C. Wainwright Reaffirms Buy Rating on AngioDynamics (ANGO) After Strong Q1 Performance - Yahoo Finance |
| 2023-02-27 | -1.4% | legal | SEC EDGAR | ANGO 8-K: 8.01 (SEC Filing) |
| 2025-01-16 | +1.3% | news | Seeking Alpha | AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares |
| 2022-11-30 | -1.3% | legal | SEC EDGAR | ANGO 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-11-15 | +1.3% | legal | SEC EDGAR | ANGO 8-K: 5.02, 5.07 (SEC Filing) |
| 2022-08-04 | +1.2% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for AngioDynamics (ANGO) - Zacks Investment Research |
| 2026-04-15 | -1.1% | expansion | MarketBeat | AngioDynamics CEO Touts Debt-Free Turnaround, Auryon Share Gains, NanoKnife Launch at Needham Conf |
| 2025-10-10 | +1.1% | executive | Quiver Quantitative | AngioDynamics Stock (ANGO) Opinions on CEO Share Purchase | ANGO Stock News - Quiver Quantitative |
| 2026-03-11 | -0.9% | news | TradingView | Reasons to Add AngioDynamics Stock to Your Portfolio for Now - TradingView |
| 2026-04-08 | +0.9% | analyst | Zacks | AngioDynamics (ANGO) Upgraded to Buy: Here's Why |
| 2026-04-08 | +0.9% | analyst | Yahoo Finance | AngioDynamics (ANGO) Upgraded to Buy: Here's Why - Yahoo Finance |
| 2022-08-31 | -0.7% | legal | SEC EDGAR | ANGO 8-K: 1.01, 1.02, 2.03 (SEC Filing) |
| 2026-04-23 | -0.7% | legal | SEC EDGAR | ANGO 8-K: 8.01 (SEC Filing) |
| 2026-04-23 | -0.7% | earnings | UBND thành phố Hải Phòng | Fair Value Assessment | AngioDynamics Inc. posts 117.8% EPS surprise beating loss estimates - Barrier to Entry - UBND thành phố Hải Phòng |
| 2026-04-23 | -0.7% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | Fair Value Assessment | AngioDynamics Inc. posts 117.8% EPS surprise beating loss estimates - Earnings Risk - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-23 | -0.7% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | ANGO (AngioDynamics Inc.) notches massive Q1 2026 EPS beat, but shares fall 1.24 percent on slight year over year revenue decline. - Trending Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-03-26 | +0.6% | news | Stock Titan | Vanguard disaggregates holdings; reports 0 shares in AngioDynamics (ANGO) - Stock Titan |
| 2026-04-10 | +0.6% | news | Zacks | AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
| 2026-04-10 | +0.6% | news | Yahoo Finance | AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance |
| 2026-01-09 | +0.5% | legal | DirectorsTalk Interviews | AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 92% Potential Upside in the Medical Technology Sector - DirectorsTalk Interviews |
| 2026-01-09 | +0.5% | earnings | simplywall.st | Assessing AngioDynamics (ANGO) Valuation After Raised Guidance And Med Tech Momentum - simplywall.st |
| 2026-02-27 | -0.4% | news | DirectorsTalk Interviews | AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 68.70% Potential Upside Amid Healthcare Innovations - DirectorsTalk Interviews |
| 2026-04-18 | -0.4% | news | Cổng thông tin điện tử tỉnh Lào Cai | AngioDynamics (ANGO) Stock: Intrinsic Value Insight (Rallies) 2026-04-18 - Hot Community Stocks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-04-20 | -0.4% | analyst | Zacks | Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade |
| 2026-04-20 | -0.4% | news | Cổng thông tin điện tử tỉnh Lào Cai | AngioDynamics (ANGO) Stock Technical Resistance (Investor Interest) 2026-04-20 - Verified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-02-20 | +0.4% | analyst | DirectorsTalk Interviews | AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 72.62% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews |
| 2025-10-12 | -0.4% | M&A | simplywall.st | AngioDynamics CEO, President & Director Acquires 1.9% More Stock - simplywall.st |
| 2026-02-19 | +0.4% | news | Stock Titan | New tumor option in liver, pancreas, kidney as NanoKnife use widens in Europe - Stock Titan |
| 2025-12-29 | -0.3% | news | Seeking Alpha | AngioDynamics: Growth Remains Under The Radar |
| 2025-12-29 | -0.3% | news | Seeking Alpha | AngioDynamics: Growth Remains Under The Radar (NASDAQ:ANGO) - Seeking Alpha |
| 2023-07-24 | -0.1% | legal | SEC EDGAR | ANGO 8-K: 5.02 and (SEC Filing) |
| 2025-08-17 | +0.1% | news | Seeking Alpha | AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul |
| 2025-08-17 | +0.1% | news | Seeking Alpha | AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul (NASDAQ:ANGO) - Seeking Alpha |
| 2025-07-16 | +0.1% | earnings | Yahoo Finance | AngioDynamics Inc (ANGO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Tariff ... - Yahoo Finance |
| 2026-03-29 | +0.1% | news | Seeking Alpha | Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag |
| 2026-03-29 | +0.1% | earnings | MarketBeat | AngioDynamics, Inc. (NASDAQ:ANGO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat |
| 2021-12-06 | +0.0% | legal | SEC EDGAR | ANGO 8-K: 8.01 (SEC Filing) |